Alcohol-related Liver Disease Clinical Trial
Official title:
Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or "dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04287920 -
Acamprosate Safe to Use in Individuals With Liver Disease.
|
Phase 2 | |
| Recruiting |
NCT04876443 -
Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
|
||
| Not yet recruiting |
NCT06305624 -
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
|
N/A | |
| Completed |
NCT01812226 -
Alcohol Biomarkers in Post-Liver Transplant Patients
|
||
| Active, not recruiting |
NCT06183710 -
Contingency Management to Incentivise Treatment Adherence in Alcohol-related Liver Disease
|
N/A | |
| Recruiting |
NCT06403332 -
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.
|
N/A | |
| Not yet recruiting |
NCT05623150 -
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
|
||
| Not yet recruiting |
NCT06269510 -
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
|
N/A |